CRB-701

DRUG2 trials

Sponsors

Corbus Pharmaceuticals Inc.

Conditions

Oropharyngeal Carcinoma (OPC)Solid Tumor, Adult

Phase 1

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

RecruitingNCT06265727

Corbus Pharmaceuticals Inc.Solid Tumor, Adult

Start: 2024-04-01End: 2027-01-27Target: 348Updated: 2026-01-08

Phase 3

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

Not yet recruitingNCT07768189

Corbus Pharmaceuticals Inc.Oropharyngeal Carcinoma (OPC)

Start: 2026-09-20End: 2029-03-01Target: 260Updated: 2026-08-31

Related Papers

A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2026-05-27

A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer.

Journal of Clinical Oncology2026-05-27

Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors.

Journal of Clinical Oncology2025-02-101 citations